Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 3(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06431256Phase 3Terminated

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

Role: collaborator

NCT01685684Phase 3Completed

Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)

Role: lead

NCT03588806Phase 4Terminated

Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills

Role: collaborator

All 3 trials loaded